Pathological cardiac hypertrophy involves multiple regulators and several signal transduction pathways. Currently, the mechanisms of it are not well understood. Differentially expressed in FDCP 6 ...
In a groundbreaking study, the regulatory role of the long noncoding RNA (lncRNA) Gm20257 in pathological cardiac hypertrophy has been elucidated, offering new insights into potential therapeutic ...
Left ventricular hypertrophy is a leading risk factor for cardiovascular morbidity and mortality. Although reverse ventricular remodelling was long thought to be irreversible, evidence from the past ...
In a recent study, the regulatory role of the long noncoding RNA (lncRNA) Gm20257 in pathological cardiac hypertrophy has been elucidated, offering new insights into potential therapeutic targets.
A new study published in Engineering has uncovered a regulatory mechanism linking lysosomal function to mitochondrial ...
When the workload on the heart increases, the ventricular wall may thicken too, known as cardiac hypertrophy. This is an adaptive response that reduces pressure on the heart and maintains the activity ...
Heart failure is the terminal stage of various cardiovascular diseases, usually characterized by pathological myocardial hypertrophy. So far, the pathogenesis of heart failure is not fully understood.
When the workload on the heart increases, the ventricular wall may thicken too, known as cardiac hypertrophy. This is an adaptive response that reduces pressure on the heart and maintains the activity ...
Hypertrophy: Hypertrophy is an increase in muscle mass/size due to an increase in the volume and cross-sectional area (CSA) of individual muscle cells. The increase in cross-sectional area can be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results